Your last cholesterol panel measured LDL, HDL, and triglycerides. It almost certainly did not measure a particle that roughly one in five people carries at a level tied to elevated cardiovascular risk, and that no amount of diet, exercise, or statin therapy will move.
That is the situation the 2026 ACC/AHA multisociety dyslipidemia guideline set out to change. Released in March, the guideline recommends testing lipoprotein(a) at least once in a lifetime in every adult, the first time a US guideline has called for universal measurement.
The particle has been known since 1963. The test has existed for decades.
A Cholesterol Particle with an Extra Protein Bolted On
Lipoprotein(a), written Lp(a) and usually said aloud as "L-P-little-a," is an LDL-like particle whose apolipoprotein B100 component is covalently linked to apolipoprotein(a), a polymorphic glycoprotein. Norwegian physician Kåre Berg first described it.
That extra protein changes its behavior. Because apo(a) resembles plasminogen but cannot activate it, the particle interferes with clot breakdown. A review in Current Cardiovascular Risk Reports summarizes the resulting profile as proatherogenic, proinflammatory, and antifibrinolytic, and notes evidence suggesting Lp(a) is substantially more atherogenic than LDL cholesterol particle for particle.
Levels are roughly 90% genetically determined and essentially fixed from childhood. Diet does not move them meaningfully. Exercise does not move them. Statins reduce LDL sharply while leaving Lp(a) largely untouched.
Evidence from epidemiology, genome-wide association studies, and Mendelian randomization supports Lp(a) as a causal contributor to atherosclerotic cardiovascular disease and to calcific aortic valve stenosis, not merely a bystander marker.
Why It Never Appeared on Your Lab Report
A standard lipid panel is a fixed set of measurements. Lp(a) is a separate order, and until this year, US guidelines never told clinicians to place it routinely. The 2018 cholesterol guideline treated it only as a risk enhancer, useful for refining estimates in people already sitting at borderline or intermediate risk. A test that is never ordered finds nothing.
Elevated is generally defined at the 80th population percentile, roughly 50 mg/dL or 125 nmol/L, and about 20% of people worldwide sit at or above it.
Above that line, the risk climbs steadily. In the Copenhagen City Heart Study, participants with extreme levels above 120 mg/dL had roughly three to four times the myocardial infarction risk of those at the bottom of the distribution.
A participant-level meta-analysis of 27,658 people across six placebo-controlled statin trials found something clinically important. Among statin-treated patients, those with Lp(a) above 50 mg/dL carried elevated risk across every quartile of achieved LDL cholesterol. Even in the lowest LDL quartile, below about 77 mg/dL, the hazard ratio was 1.38. Driving LDL down does not erase the Lp(a) problem.
What the 2026 Guideline Changed
The Lp(a) recommendation is one of several shifts. The full guideline retires and replaces the 2018 document, restores explicit LDL and non-HDL cholesterol treatment goals scaled to risk, adds selective apolipoprotein B measurement, expands coronary artery calcium scoring, and replaces the Pooled Cohort Equations with the American Heart Association's PREVENT equations. A guideline-at-a-glance summary in JACC lays the changes against the 2018 version. Guidance now extends across the lifespan, including special considerations for testing people under 18.
An elevated Lp(a) result does not point to a specific new treatment. It functions as a risk-enhancing finding that argues for managing everything else more aggressively, LDL cholesterol above all. PCSK9-directed therapies lower Lp(a) by roughly 20% to 30%, but none is approved for that purpose.
Four Drugs Are Coming, and None Is Approved
The reason cardiologists are suddenly urgent about a test they largely ignored for 40 years is that treatment may finally be arriving.
Four candidates are in outcome trials. Pelacarsen, an antisense oligonucleotide, is furthest along. Its HORIZON trial enrolled 8,323 patients with established cardiovascular disease and Lp(a) of at least 70 mg/dL, and results are expected before the end of 2026. Olpasiran, lepodisiran, and the oral agent muvalaplin follow behind, with completion dates stretching to 2031.
Phase 2 data show Lp(a) reductions ranging from roughly 80% to more than 95%. What no trial has yet shown is that lowering Lp(a) prevents heart attacks and strokes. HORIZON is the first outcomes trial for any of these drugs, and its result will define whether the field advances or stalls.
Until then, an Lp(a) test tells you about risk, not about a prescription. Anyone who wants the measurement, particularly those with a family history of early heart disease or an unexplained cardiac event, should raise it with their own physician rather than act on a number alone.
Key Questions Answered
What is Lp(a)?
A cholesterol-carrying particle similar to LDL but with an additional protein, apolipoprotein(a), attached. Levels are roughly 90% genetically determined and stable across life.
Why isn't it on a normal cholesterol panel?
It requires a separate test order. Until the 2026 guideline, no US guideline recommended measuring it routinely in everyone.
What level is considered high?
Roughly 50 mg/dL, or about 125 nmol/L, corresponding to the 80th population percentile. About one in five people worldwide meet or exceed it.
Can diet or statins lower it?
No. Lifestyle changes and statin therapy do not meaningfully reduce Lp(a), which is why the risk persists even in patients whose LDL is well controlled.
Is there a treatment?
Not yet specifically. Four drugs are in late-stage outcome trials; none is approved for lowering Lp(a), and no trial has yet shown that lowering it prevents cardiovascular events.
What should someone with a high result do?
Discuss it with a clinician. The guideline treats elevated Lp(a) as a reason to manage other risk factors more aggressively, particularly LDL cholesterol.
